More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$453147370
EPS
-0.34
P/E ratio
--
Price to sales
6.34
Dividend yield
--
Beta
1.28843
Previous close
$11.62
Today's open
$11.92
Day's range
$11.77 - $12.88
52 week range
$5.65 - $13.25
show more
CEO
Jeffrey S. Hackman
Employees
29
Headquarters
Research Triangle Park, NC
Exchange
NASDAQ Capital Market
Shares outstanding
35305117
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
Adherex Technologies (FENC) is on the Move, Here's Why the Trend Could be Sustainable
Adherex Technologies (FENC) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Zacks Investment Research • 20 hours ago

How Much Upside is Left in Adherex Technologies (FENC)? Wall Street Analysts Think 57.8%
The consensus price target hints at a 57.8% upside potential for Adherex Technologies (FENC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Zacks Investment Research • Nov 13, 2026

What Makes Adherex Technologies (FENC) a New Strong Buy Stock
Adherex Technologies (FENC) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks Investment Research • Nov 13, 2026

Adherex Technologies Q3 Earnings Call Highlights
Fennec Pharmaceuticals NASDAQ: FENC reported third-quarter net product sales of $19.4 million, up 56% from a year earlier, as use of its hearing-protection drug PEDMARK expanded among new and existing customers.
MarketBeat • Nov 12, 2026

Fennec Pharmaceuticals Inc. (FENC) Q3 2026 Earnings Call Transcript
Fennec Pharmaceuticals Inc. (FENC) Q3 2026 Earnings Call Transcript
Seeking Alpha • Nov 12, 2026

Fennec Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update
~ Third Quarter 2026 Net Product Sales of $19.4 Million, Up 56% Year over Year ~ ~ Third Quarter 2026 Non-GAAP Adjusted EBITDA of $5.8 Million ~ ~ With $6.7 Million in Positive Cash Flow from Operations, Cash Position in the Third Quarter 2026 Grew to $48.7 Million ~ ~ Record Number of Patients and Planned Infusions Carried into the Fourth Quarter 2026 ~ ~ Management to Host Conference Call Today at 8:30 a.m. ET ~ RESEARCH TRIANGLE PARK, N.C.
GlobeNewsWire • Nov 12, 2026

Adherex Technologies Inc. (FENC) Q3 Earnings and Revenues Beat Estimates
Adherex Technologies Inc. (FENC) came out with quarterly earnings of $0.12 per share, beating the Zacks Consensus Estimate of $0.09 per share. This compares to a loss of $0.02 per share a year ago.
Zacks Investment Research • Nov 12, 2026

Fennec Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 12, 2026
RESEARCH TRIANGLE PARK, N.C., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its third quarter 2026 financial results before the opening of the U.S. financial markets on Thursday, November 12, 2026. Management will host a conference call and webcast that day to discuss the Company's financial and business results.
GlobeNewsWire • Nov 6, 2026

Fennec Pharmaceuticals Announces Oral Presentation of Detailed Results from Investigator-Initiated Phase 2 STS-J01 Clinical Study of Pedmark® in Japan at SIOP 2026
~ Primary Endpoint Met: American Speech-Language-Hearing Association (ASHA)-Defined Hearing Loss Occurred in 24.0% of Patients Versus the Prespecified Historical Benchmark of 56.4% (P=0.001) ~
GlobeNewsWire • Sep 17, 2026

Can Adherex Technologies (FENC) Climb 26.53% to Reach the Level Wall Street Analysts Expect?
The mean of analysts' price targets for Adherex Technologies (FENC) points to a 26.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Zacks Investment Research • Aug 12, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Fennec Pharmaceuticals Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.